# Three Compounds, Three Very Different Evidence Bases

> GHK-Cu vs Ipamorelin vs Tesamorelin — Clean Peptides Lab — Side-by-side comparison of GHK-Cu, ipamorelin and tesamorelin on mechanism, evidence maturity, regulatory status and lab-grade quality signals in the peer-reviewed literature.

**COMPARE**

Lined up side by side on mechanism, human trial depth, regulatory status and what "lab-grade" actually means for each one.

## The short version

These three compounds are not interchangeable, even though vendors sometimes bundle them together as "research peptides." GHK-Cu is a naturally occurring copper-binding tripeptide, best documented as a topical cosmetic ingredient. Ipamorelin is a synthetic growth-hormone secretagogue with a very thin human trial record. Tesamorelin is a synthetic hormone analogue with a genuine FDA approval and a real regulatory dossier behind it.

Those differences matter most for the question this hub asks: what does "lab-grade" or "high purity" actually buy a reader for each one. A purity certificate means something different attached to an FDA-regulated drug than attached to an unregulated research-chemical vial, and the table below is organized around that distinction as much as around mechanism.

## Mechanism, at a glance

| Compound | Class | Primary mechanism | Route best studied |
|---|---|---|---|
| GHK-Cu | Copper-binding tripeptide | Stimulates fibroblast collagen/elastin synthesis; broad gene-expression shift toward repair pathways [2][6] | Topical (cosmetic) |
| Ipamorelin | Growth-hormone secretagogue | Selectively activates the ghrelin receptor (GHS-R1a) on pituitary cells, triggering a GH pulse without raising cortisol or prolactin [11] | Subcutaneous / IV (research) |
| Tesamorelin | GHRH analogue | Binds the GHRH receptor on pituitary somatotrophs, amplifying the body's own pulsatile GH release [16] | Subcutaneous (approved drug) |

## Evidence maturity

| Compound | Deepest human evidence | Largest trial in this dataset | Regulatory status |
|---|---|---|---|
| GHK-Cu | Small topical trials (n roughly 13-71) | 45-person hair-growth RCT of a combination formula [3] | Legal cosmetic ingredient; no drug approval for any route |
| Ipamorelin | One short Phase 2 trial, primary endpoint missed | 114-person postoperative-ileus RCT [10] | Never approved as a drug; removed from the 503A compounding list in 2024 |
| Tesamorelin | Multiple RCTs plus a 2026 meta-analysis of five pooled trials [13] | 273-person, 52-week program [17] | FDA-approved (NDA, 2010) for HIV-associated lipodystrophy |

On raw evidence volume, tesamorelin is furthest along, GHK-Cu sits in the middle with a long but mostly cosmetic-topical record, and ipamorelin has the least — a single human efficacy trial that did not hit its primary endpoint [10].

## What 'lab-grade' means for each

For **tesamorelin**, the approved product is manufactured under FDA quality-control requirements — identity, purity and batch consistency are a condition of approval, not a marketing claim. For **GHK-Cu**, the strongest quality assurance sits with topical cosmetic manufacturing standards, which are real but distinct from pharmaceutical drug-grade requirements; injectable research-grade GHK-Cu carries no equivalent oversight [1]. For **ipamorelin**, there is no approved product at all — every batch sold today is research-grade material from an unregulated supplier, and the only investigational-grade batch that has ever been through controlled human testing was made specifically for the 2014 trial, not what circulates in research-chemical markets [10].

Across all three, a chromatography certificate reporting a high purity percentage answers a narrow question — what was in that specific batch on the day it was tested — and does not answer the broader one a reader usually wants answered: whether the compound has been shown, in controlled human trials, to do what it is marketed to do.

## Reading the safety literature across all three

Tesamorelin's safety picture is the most complete: a dedicated NIH liver-safety monograph rates it an unlikely cause of liver injury [14], and its pooled trial data show no excess of serious adverse events [13]. Ipamorelin's safety picture leans heavily on *class-level* signals borrowed from related compounds — most notably a cardiotoxicity finding in a structurally different GHS-R1a agonist, not ipamorelin itself — because no long-duration ipamorelin-specific safety study exists in any species [9]. GHK-Cu's caution set is almost entirely about topical use — irritation, formulation stability with other actives — with injectable or systemic use flagged as effectively unstudied in humans [1].

Read each compound's own page — [GHK-Cu](/ghk-cu), [ipamorelin](/ipamorelin), [tesamorelin](/tesamorelin) — for the full findings and cautions, or the [frequently asked questions](/faq) for shorter, direct answers.

---

Clean Peptides Lab reads the purity, testing and quality-signal literature on GHK-Cu, ipamorelin and tesamorelin; it runs no assays, holds no certification, and is a reading desk, not a laboratory.